A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
Abstract. Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer.
People also ask
What is the life expectancy of someone with BRCA1?
What happens if you have a mutation in the BRCA1 and BRCA2 genes?
What does it mean when a woman has BRCA1 and BRCA2?
Are the BRCA1 and BRCA2 genes associated with an increased risk of ovarian cancer?
Jun 22, 2012 · Women who carry mutations in BRCA1 or BRCA2 are at a substantially increased risk of developing breast and/or ovarian cancers. Lifetime risks ...
The IRS1 Gly972Arg single-nucleotide polymorphism, which affects insulin-like growth factor and insulin signaling, modifies ovarian cancer risk in BRCA1 and ...
Dec 6, 2012 · Correction: A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 ...
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. / Ding, Yuan ...
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer ...
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. YC Ding ...
SWE-BRCA. / A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger ...